Analyst downgrades: LZ, BMRN and NVS
Posted Jun 12th 2008 11:21AM by Eric Buscemi
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Novartis AG ADS (NVS)
.gif)
MOST NOTEWORTHY: Lubrizol, BioMarin Pharmaceutical and Novartis were today's noteworthy downgrades:
- Jefferies downgraded shares of Lubrizol (NYSE:LZ) to Hold from Buy as they expect persistent raw material cost pressures to limit upside over the next few quarters. The firm lowered their target price to $60 from $65.
- Citigroup cut BioMarin (NASDAQ:BMRN) to Hold from Buy after their survey indicated an upside surprise from the Kuvan launch is unlikely. The firm lowered their target price to $37 from $42.
- HSBC downgraded shares of Novartis (NYSE:NVS) to Underweight from Neutral following the company's stake in Alcon (NYSE:ACL) as they believe it dilutes the company's return on assets.
OTHER DOWNGRADES:
Tags: analyst downgrades, AnalystDowngrades, BRMN, DWA, KGC, LZ, MSO, NVS, WMI
Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
